BioVie Shares Results on Phase 2a Clinical Trial

BioVie shared top-line results for its Phase 2a clinical trial of BIV201 in patients with refractory ascites due to advanced liver cirrhosis.

BioVie Reviews Key Accomplishments from 2017 and Updates Phase 2a Clinical Trial

BioVie (OTCQB: BIVI), reviewed key milestones achieved over the past year and provided a general update on the progress of...